For most patients, a medical weight loss program with semaglutide or tirzepatide delivers significant, sustained results. But for some men, progress is slower than expected — appetite suppression works, but the scale moves less than it should, and lean mass continues to decline. One underexplored reason is testosterone deficiency, which independently drives fat gain and metabolic dysfunction and can blunt the effectiveness of GLP-1 therapy.
The Testosterone-Weight Connection in Men
Testosterone plays a central role in male body composition. Low testosterone is directly associated with increased visceral fat accumulation — the metabolically active fat stored around abdominal organs that drives insulin resistance, inflammation, and cardiovascular risk.
The mechanism is straightforward: testosterone deficiency leads to reduced muscle mass, which lowers resting metabolic rate, which makes fat gain easier and fat loss harder. Hypogonadal men — those with clinically low testosterone — have significantly higher rates of metabolic syndrome, type 2 diabetes, and obesity compared to eugonadal men of similar age.
The relationship is bidirectional. Adipose tissue converts testosterone to estrogen via aromatase, so more fat means lower testosterone. Losing fat can modestly improve testosterone levels on its own — but this effect is often insufficient to normalize testosterone in men who are clinically hypogonadal.
How GLP-1 Medications Interact with Testosterone Levels
GLP-1 therapy produces significant fat loss — and as visceral fat decreases, testosterone levels may rise modestly due to reduced aromatase activity. Some men see meaningful testosterone improvement alongside GLP-1 treatment, particularly if their low testosterone was largely driven by adiposity.
However, for men with primary or secondary hypogonadism (testosterone deficiency not primarily caused by obesity), GLP-1 therapy alone will not normalize testosterone levels. Starting GLP-1 therapy without evaluating testosterone in men may produce suboptimal body composition outcomes — particularly lean mass preservation — even as fat loss is achieved.
This is why Dr. Jaqua's metabolic evaluation includes testosterone alongside the standard GLP-1 candidacy labs for male patients.
Signs That Testosterone Might Be Involved in Your Weight Gain
Some men present for GLP-1 weight loss evaluation with symptoms that suggest testosterone deficiency is a contributing factor — not just excess caloric intake or sedentary lifestyle:
- Fatigue disproportionate to activity level or sleep quality
- Difficulty building or maintaining muscle mass despite exercise
- Progressive loss of motivation, mood changes, or brain fog
- Reduced libido alongside weight gain
- Weight concentrated around the abdomen, with little response to prior diet attempts
These symptoms overlap significantly between low testosterone and metabolic dysfunction, which is exactly why labs — not symptoms alone — determine whether testosterone replacement is clinically indicated. A testosterone panel drawn at the same visit as GLP-1 candidacy labs adds minimal complexity and maximum diagnostic value.
Combined GLP-1 and TRT — What the Evidence Shows
In hypogonadal men, combination therapy with a GLP-1 medication and testosterone replacement therapy addresses the problem from both ends: GLP-1 targets adiposity and metabolic signaling, while TRT addresses testosterone deficiency and lean mass maintenance. The combination can produce superior body composition outcomes compared to either therapy alone in appropriately selected patients.
Physician supervision is essential for combination therapy. GLP-1 medications and TRT have distinct dosing schedules, monitoring requirements, and potential interactions. Dr. Jaqua manages both protocols when indicated — not as a bundled package, but as two individually appropriate treatments for a patient with two clinically documented conditions.
In the STEP 1 clinical trial, participants using semaglutide (2.4 mg weekly) lost an average of 14.9% of body weight over 68 weeks (Wilding et al., NEJM 2021). Individual results vary based on adherence, metabolic starting point, diet, and activity — and, in men, hormonal baseline.
TRT Is Not a Weight Loss Medication
This is an important distinction: testosterone replacement therapy is not prescribed for weight loss. TRT addresses a documented testosterone deficiency. In men with clinically low testosterone, correcting that deficiency supports better body composition outcomes — it preserves lean mass, reduces visceral fat accumulation, and improves metabolic function. But these are outcomes of treating hypogonadism, not a weight loss program.
If a man has normal testosterone levels, TRT is not clinically indicated for weight management purposes. Dr. Jaqua prescribes TRT when labs and symptoms support a diagnosis of hypogonadism — not as an adjunct to GLP-1 therapy for all male patients.
The Vitality Metabolic Evaluation — Why We Test Both
At Vitality, the initial evaluation for male patients presenting for weight loss includes testosterone alongside the standard GLP-1 candidacy labs (fasting glucose, HbA1c, lipid panel, thyroid function, basic metabolic panel). This is not a upsell — it's a complete metabolic picture.
If testosterone is clinically low and GLP-1 therapy is indicated, Dr. Jaqua discusses both options together. If testosterone is normal, TRT is not recommended. If GLP-1 candidacy criteria are not met but testosterone is low, TRT may be appropriate on its own. Each patient gets a clinical recommendation based on their actual lab results — not a preset protocol.
Labs are drawn on-site at our Boerne location, with results the following day. Your consultation includes a full review of all lab findings before any prescription is written.
Frequently Asked Questions
Can I take semaglutide and testosterone at the same time?
Yes, in many cases. GLP-1 medications (semaglutide, tirzepatide) and testosterone replacement therapy address different physiological systems and can be used concurrently under physician supervision. Dr. Jaqua evaluates both during your metabolic workup and manages dosing and monitoring for each. Combined therapy is not appropriate for every patient — it depends on your labs, health history, and clinical indication for both. A physician evaluation, not an online decision, is how this is determined.
Does low testosterone make it harder to lose weight on GLP-1?
Yes. Testosterone deficiency reduces muscle mass and lowers resting metabolic rate, making fat loss harder even when appetite is suppressed by GLP-1 therapy. In hypogonadal men, the GLP-1-driven reduction in appetite may produce fat loss, but lean mass decline can blunt the metabolic benefits and reduce total weight loss compared to eugonadal men on the same protocol. Correcting testosterone deficiency alongside GLP-1 therapy can improve body composition outcomes — both fat loss and lean mass preservation — in appropriately selected patients.
Will TRT alone help me lose weight without a GLP-1?
TRT is not a weight loss medication and is not prescribed for that purpose. In men with clinically documented testosterone deficiency, correcting that deficiency can improve body composition — reduced visceral fat, preserved lean mass, better insulin sensitivity — as outcomes of treating hypogonadism. These are metabolic improvements, not weight loss treatment. If a man has clinically low testosterone and does not meet GLP-1 candidacy criteria, TRT alone may be the appropriate clinical recommendation. If both conditions are present, both may be addressed concurrently. Dr. Jaqua makes this determination based on your labs and clinical picture, not a standard protocol.
Ready to Evaluate Your Full Metabolic Picture?
For men whose weight gain may have a hormonal component, a comprehensive evaluation is the first step. Vitality's medical weight loss program and testosterone replacement therapy evaluations are available together at your initial consultation — one visit, comprehensive labs, and a clinical recommendation covering both.
Your initial consultation is free. Labs are drawn same-day. Dr. Jaqua reviews all results with you before recommending any treatment.
References
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” N Engl J Med. 2021;384:989–1002. (STEP 1 — average 14.9% body weight loss at 68 weeks with semaglutide 2.4 mg vs. 2.4% with placebo.)
- Traish AM. “Testosterone deficiency, obesity, metabolic syndrome and the metabolic disorder — a bidirectional relationship.” Rev Endocr Metab Disord. 2022;23:629–646.
- Grossmann M, et al. “Testosterone and the metabolic syndrome.” Expert Rev Endocrinol Metab. 2019;14(3):203–213.